Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

(2010) B. A. Walker et al.   BLOOD

Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome

(2010) N. J. Dickens et al.   CLINICAL CANCER RESEARCH

Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution

(2010) Hongcang Gu et al.   NATURE METHODS

A monoclonal gammopathy precedes multiple myeloma in most patients

(2009) B. M. Weiss et al.   BLOOD

DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia

(2009) L. Milani et al.   BLOOD

Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia

(2009) M. Kanduri et al.   BLOOD

Differential repetitive DNA methylation in multiple myeloma molecular subgroups

(2009) V. Bollati et al.   CARCINOGENESIS

GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer

(2009) D. M.E.I. Hellebrekers et al.   CLINICAL CANCER RESEARCH

TGFβR2aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma

(2009) Fabrício de Carvalho et al.   INTERNATIONAL JOURNAL OF CANCER

Frequent downregulation or loss of CD79a expression in plasma cell myelomas: Potential clue for diagnosis

(2009) Takehiro Tanaka et al.   PATHOLOGY INTERNATIONAL

Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers

(2009) Yutaka Kondo   YONSEI MEDICAL JOURNAL

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

(2008) Y. Jiang et al.   BLOOD

Aberrant Promoter Methylation of Multiple Genes during Pathogenesis of Bladder Cancer

(2008) M. Brait et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications

(2008) P. E. Leone et al.   CLINICAL CANCER RESEARCH

Cthrc1 Selectively Activates the Planar Cell Polarity Pathway of Wnt Signaling by Stabilizing the Wnt-Receptor Complex

(2008) Shinji Yamamoto et al.   DEVELOPMENTAL CELL

Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma

(2008) Guanghua Chen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma

(2008) Marina Tshuikina et al.   EXPERIMENTAL HEMATOLOGY

DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status

(2008) B L Pike et al.   LEUKEMIA

Multiple Myeloma-Related WHSC1/MMSET Isoform RE-IIBP Is a Histone Methyltransferase with Transcriptional Repression Activity

(2008) J.-Y. Kim et al.   MOLECULAR AND CELLULAR BIOLOGY

Cthrc1 Is a Positive Regulator of Osteoblastic Bone Formation

(2008) Hiroaki Kimura et al.   PLoS One

The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor

(2007) J. Marango et al.   BLOOD